Noninvasive imaging of cell proliferation following mitogenic extracellular kinase inhibition by PD0325901

Molecular Cancer Therapeutics

Volumn 7, Issue 9, 2008, Pages 3112-3121

  Leyton, Julius ^a   Smith, Graham ^a   Lees, Mark ^a   Perumal, Meg ^a   Nguyen, Quang De ^a   Aigbirhio, Franklin I ^b   Golovko, Oksana ^b   He, Quimin ^c   Workman, Paul ^d   Aboagye, Eric O ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3' FLUOROTHYMIDINE F 18; B RAF KINASE; CYCLIN D1; K RAS PROTEIN; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; RADIOPHARMACEUTICAL AGENT; THYMIDINE KINASE 1; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLON CANCER; COLON CARCINOMA; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG UPTAKE; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VIVO STUDY; LABELING INDEX; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; ONCOGENE K RAS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; XENOGRAFT;

ANIMALS; BENZAMIDES; CASPASE 3; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; DIDEOXYNUCLEOSIDES; DIPHENYLAMINE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KI-67 ANTIGEN; MAP KINASE KINASE 1; MICE; MICE, INBRED BALB C; PHOSPHORYLATION; POSITRON-EMISSION TOMOGRAPHY; RNA, MESSENGER; THYMIDINE KINASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 54049121486     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-0264     Document Type: Article

References (27)

1. Hoshino R, Chatani Y, Yamori T, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999;18:813-22.
2. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
3. Wellbrock C, Ogilvie L, Hedley D, et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res 2004;64:2338-42.
4. Smith G, Carey FA, Beattie J, et al. Mutations in APC, Kirsten-ras, and p53-alternative genetic pathways to colorectal cancer. Proc Natl Acad Sci U S A 2002;99:9433-8.
5. Adjei AA, Cohen RB, Franklin W, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 2008;26:2139-46.
6. Davies BR, Logie A, McKay JS, et al. AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in preclinical models. Mol Cancer Ther 2007;6:2209-19.
7. Lorusso PM, Adjei AA, Varterasian M, et al. Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 2005;23:5281-93.
8. Rinehart J, Adjei AA, Lorusso PM, et al. Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 2004;22:4456-62.
9. Solit DB, Garraway LA, Pratilas CA, et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006;439:358-62.
10. Smalley KS, Contractor R, Haass NK, et al. Ki67 expression levels are a better marker of reduced melanoma growth following MEK inhibitor treatment than phospho-ERK levels. Br J Cancer 2007;96:445-9.
11. Barthel H, Perumal M, Latigo J, et al. The uptake of 3′-deoxy- 3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels. Eur J Nucl Med Mol Imaging 2005;32:257-63.
12. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-7.
13. Leyton J, Alao JP, Da Costa M, et al. In vivo biological activity of the histone deacetylase inhibitor LAQ824 is detectable with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Cancer Res 2006;66:7621-9.
14. Leyton J, Latigo JR, Perumal M, et al. Early detection of tumor response to chemotherapy by 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 2005;65:4202-10.
15. Leyton J, Lockley M, Aerts JL, et al. Quantifying the activity of adenoviral E1A CR2 deletion mutants using renilla luciferase bioluminescence and 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography imaging. Cancer Res 2006;66:9178-85.
16. Solit DB, Santos E, Pratilas CA, et al. 3′-Deoxy-3′-[18F] fluorothymidine positron emission tomography is a sensitive method for imaging the response of BRAF-dependent tumors to MEK inhibition. Cancer Res 2007;67:11463-9.
17. Oh SJ, Mosdzianowski C, Chi DY, et al. Fully automated synthesis system of 3′-deoxy-3"-[18F]fluorothymidine. Nucl Med Biol 2004;31:803-9.
18. Workman P, Balmain A, Hickman JA, et al. UKCCCR guidelines for the welfare of animals in experimental neoplasia. Lab Anim 1988;22:195-201.
19. Barthel H, Cleij MC, Collingridge DR, et al. 3′-Deoxy-3′- [18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003;63:3791-8.
20. Balmanno K, Cook SJ. Sustained MAP kinase activation is required for the expression of cyclin D1, p21Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 1999;18:3085-97.
21. Weber JD, Raben DM, Phillips PJ, Baldassare JJ. Sustained activation of extracellular-signal-regulated kinase 1 (ERK1) is required for the continued expression of cyclin D1 in G1 phase. Biochem J 1997;326:61-8.
22. Cruzalegui FH, Cano E, Treisman R. ERK activation induces phosphorylation of Elk-1 at multiple S/T-P motifs to high stoichiometry. Oncogene 1999;18:7948-57.
23. Galetic I, Maira SM, Andjelkovic M, Hemmings BA. Negative regulation of ERK and Elk by protein kinase B modulates c-Fos transcription. J Biol Chem 2003;278:4416-23.
24. Buck AK, Halter G, Schirrmeister H, et al. Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med 2003;44:1426-31.
25. Kenny LM, Vigushin DM, Al-Nahhas A, et al. Quantification of cellular proliferation in tumor and normal tissues of patients with breast cancer by [18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 2005;65:10104-12.
26. Chan F, Sun C, Perumal M, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007;6:3147-57.
27. Kenny L, Coombes RC, Vigushin DM, et al. Imaging early changes in proliferation at 1 week post chemotherapy: a pilot study in breast cancer patients with 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 2007;34:1339-47.